Ozempic and Benzodiazepines: Drug Interaction Guide
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes, dosed by weekly subcutaneous injection at 0.25 to 2.0 mg. Benzodiazepines are a class of sedative-hypnotic drugs (examples include alprazolam, lorazepam, clonazepam, diazepam, and midazolam) used for anxiety, insomnia, seizure disorders, and procedural sedation. This page addresses whether the two can be taken together, not whether a specific benzodiazepine dose needs to change for a specific patient.
Direct answer
No dose adjustment for either drug is required by current FDA labeling when semaglutide and an oral benzodiazepine are used together. Semaglutide's known pharmacologic effect on gastric emptying is a plausible mechanism for a mild, transient delay in how quickly an oral benzodiazepine is absorbed, but this is a difference in speed of onset, not in total drug exposure. This combination is not the same question as sedation risk from other drugs (opioids, alcohol, other CNS depressants), which carries a separately established and larger risk with benzodiazepines and should not be conflated with the semaglutide interaction discussed here.
The paragraph above is the core, evidence-anchored answer for this page. Everything below expands on the mechanism, what is and is not established, and what a prescriber or pharmacist should verify before relying on it for an individual patient.
Why this pairing gets flagged in interaction checkers
Semaglutide slows gastric emptying as part of its normal pharmacology; this is a labeled effect and part of how it reduces appetite and post-meal glucose excursions. Because gastric emptying speed affects how quickly an oral drug reaches the small intestine for absorption, any oral medication taken around the same time as semaglutide can, in theory, have altered absorption timing. Drug interaction databases flag this as a mechanism-based, generally low-severity interaction rather than a pharmacokinetic interaction proven to change drug levels.
The Ozempic prescribing information addresses this class of concern directly: semaglutide "has the potential to impact the absorption of concomitantly administered oral medications" because of delayed gastric emptying. The manufacturer's pharmacokinetic interaction program, referenced in the FDA label, included an oral midazolam probe study designed to test this (FDA label). Midazolam is a standard CYP3A4 probe substrate used across many drug development programs precisely because it is sensitive to metabolic interactions.
What this does and does not mean mechanistically
Semaglutide's known interaction mechanisms, per its label, are limited to the gastric-emptying effect. There is no established CYP3A4, CYP2C19, or P-glycoprotein inhibition or induction from semaglutide, and no established effect on hepatic glucuronidation enzymes (UGTs). This distinction matters for benzodiazepines because they are metabolized through two different pathways:
- CYP-metabolized benzodiazepines: alprazolam, midazolam, and triazolam (CYP3A4); diazepam (CYP2C19 and CYP3A4).
- Glucuronidation-metabolized benzodiazepines: lorazepam, oxazepam, and temazepam, which bypass the CYP system.
Because semaglutide has no established CYP-inhibiting effect, the CYP-metabolized group is not expected to show a metabolic interaction, and the glucuronidated group has even less theoretical exposure to any semaglutide-related enzyme effect. Both groups remain subject to the same gastric-emptying-related absorption-timing consideration, since that mechanism is independent of which liver pathway ultimately clears the drug.
Evidence-status interaction assessment
| Status | Claim | Basis | What a clinician or pharmacist should still verify |
|---|---|---|---|
| Established | Semaglutide delays gastric emptying as a labeled pharmacologic effect. | FDA prescribing information. | Confirm current label language has not changed with newer formulations or updates. |
| Established | No dose adjustment for semaglutide or benzodiazepines is currently recommended by the FDA label for this combination. | FDA prescribing information. | Check the specific benzodiazepine's own label for any semaglutide-specific caution, since GLP-1 labeling is updated periodically. |
| Established (general pattern, exact figures unverified here) | Oral drug exposure (AUC) for a CYP3A4 probe medication tested with semaglutide was not meaningfully changed; Cmax and time-to-peak showed a modest shift. | FDA pharmacokinetic interaction program described in the label. | Verify the exact percentage change and the specific comparator drug directly against the current label PDF before quoting a number to a patient or in a chart note. |
| Plausible but not established as clinically meaningful | Onset of an as-needed oral benzodiazodiazepine (for example, alprazolam taken for acute anxiety) may be modestly slower during semaglutide dose titration, when GI effects are most pronounced. | Mechanistic inference from the gastric-emptying effect; not a dedicated onset-timing trial for benzodiazepines specifically. | Ask the patient about timing of relief and re-dosing behavior; do not assume this applies equally to all benzodiazepines or all patients. |
| Not established | Semaglutide increases sedation, fall risk, or benzodiazepine-related adverse effects through a pharmacologic (as opposed to symptom-overlap) mechanism. | No CNS depressant mechanism is described in the label; fatigue and nausea during GLP-1 titration are separate, documented effects that could be subjectively confused with sedation. | Screen for daytime drowsiness at follow-up, but attribute it carefully rather than assuming a drug-drug interaction. |
| Not established | A specific quantified rate of nausea or GI symptoms during a named semaglutide trial, or a specific gastric half-emptying time in minutes, as sometimes cited in interaction summaries. | These numeric claims could not be verified against a confirmed primary source for this revision. | Pull the original trial or the current label directly if a specific percentage or time value is needed for patient counseling or documentation. |
Which benzodiazepines carry the lowest theoretical friction
Lorazepam, oxazepam, and temazepam are cleared by glucuronidation rather than CYP enzymes, which removes the CYP3A4 pathway from consideration entirely for those drugs. This does not mean they are "safer" in the sense of being differently effective or having a different sedation profile; it means there is one less theoretical interaction mechanism to consider. Alprazolam, midazolam, triazolam, and diazepam depend on CYP pathways that semaglutide has not been shown to affect, so the practical difference between the two groups for this specific interaction is small.
Clonazepam and diazepam have long elimination half-lives (clonazepam is commonly cited in the 18 to 50 hour range). For a drug dosed on a fixed schedule and taken to steady state, a small delay in absorption timing after any single dose has little effect on the overall blood level trajectory, because it evens out over repeated dosing.
Monitoring and counseling points
Two situations deserve more attention than routine, stable co-administration:
During semaglutide dose titration. GI side effects (nausea, delayed fullness) are most common in the early weeks and after each dose increase, per the FDA label and the drug's overall safety profile. An as-needed benzodiazepine taken during this window may feel slower to work. The clinically important counseling point is not to re-dose early on the assumption the first dose "didn't work," since that risks unintended over-sedation from an accumulating effect of two doses arriving close together, rather than from a true drug-drug interaction.
Patients with pre-existing gastroparesis or significant GI symptoms. Semaglutide's label advises caution around severe gastroparesis. In a patient with delayed gastric emptying from another cause, adding semaglutide could compound the absorption-timing effect for any oral medication, benzodiazepines included. This is a reason for closer symptom tracking, not a reason to avoid the combination outright, and any patient with a gastroparesis diagnosis should have this discussed individually with the prescribing clinician.
Beyond these two scenarios, routine co-administration of semaglutide and a benzodiazepine does not require special precautions based on currently available label data.
What this page does not cover
This is not guidance on stopping or starting a benzodiazepine. Abrupt benzodiazepine discontinuation can cause withdrawal, including seizures, and should never be done without medical supervision, regardless of what other medications a patient is taking. This page also does not address benzodiazepine interactions with alcohol, opioids, or other sedating drugs, which carry separately established and generally larger risks than anything described here, and should be evaluated on their own terms with a prescriber or pharmacist.
Evidence boundary
Established: semaglutide delays gastric emptying; this is a labeled mechanism. Established: the FDA's pharmacokinetic interaction program did not identify a change in overall drug exposure for oral co-medications tested, and no dose adjustment for benzodiazepines is currently required. Plausible but unproven: a clinically noticeable slower onset for as-needed benzodiazepines during semaglutide titration, based on mechanism rather than a dedicated benzodiazepine-specific onset trial. Not established: any direct pharmacologic sedation-enhancing effect of semaglutide, or the specific numeric figures (exact percentage changes, minute-level gastric emptying delays, trial-specific side-effect rates) that sometimes circulate in secondary interaction summaries. Those figures require direct verification against the current FDA label and the original trial publications before they are used in patient materials or clinical documentation.
Questions worth asking your prescriber or pharmacist
Can I take my anxiety medication and Ozempic on the same day? Yes, this is a labeled, low-severity interaction with no required dose change, though onset may be slightly delayed during the early weeks of Ozempic.
Should I take my benzodiazepine on an empty stomach to avoid any delay? This is a reasonable, low-risk strategy some clinicians suggest, though it is not a labeled requirement. Confirm with your prescriber whether it applies to your specific medication and dosing schedule.
Does the interaction get worse at higher Ozempic doses? The gastric-emptying effect is part of semaglutide's core pharmacology across its dose range, but no dose level has been shown to require a benzodiazepine dose change. If you are titrating to a higher Ozempic dose, expect any absorption-timing effect to be most noticeable in the days after each dose increase.
Is this the same as the interaction risk from mixing benzodiazepines with alcohol or opioids? No. Those combinations carry an established, separate, and generally more serious risk related to combined CNS depression. The semaglutide interaction described here is about absorption timing, not additive sedation.
If you experience unusual drowsiness, confusion, difficulty breathing, or signs of an allergic reaction after starting either medication, seek urgent medical care rather than waiting for a routine follow-up.
References
- Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
- U.S. Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug
- European Medicines Agency. Ozempic European Public Assessment Report (EPAR). https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic